Pilot study to evaluate the next-dose transition from Zolpidem to Lemborexant for treatment of insomnia.

  • STATUS
    Recruiting
Updated on 23 November 2020
zolpidem

Summary

The purpose of this study is to evaluate the next-dose transition from Zolpidem (Ambien) to Lamborexant for treatment of insomnia.

 

Description

Compensation for time and travel for all completed study visits for qualified participants.

Details
Condition Insomnia
Clinical Study IdentifierTX227885
Last Modified on23 November 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

Currently taking Zolpidem (or other brand), 18 or older, not other sleeping disorder, 7 hours or more in bed each night, and otherwise in general good health
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note